IP Library › Granted Patent US 9,649,323
Granted Patent B2
US 9,649,323 · App. 13/474,998 · Granted May 16, 2017

Methods of using dual-effect liposome in therapy

Inventors: Chin-Tin Chen (Taipei, TW); Tsuimin Tsai (Taipei, TW)
Assignees: NATIONAL TAIWAN UNIVERSITY; TAIPEI MEDICAL UNIVERSITY
A61K31/704A61K9/0019A61K9/1271A61K33/24A61K41/0071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,649,323
App. No.
13/474,998
Granted
May 16, 2017
Kind
B2
Abstract

The invention provides a method for treating target in need of such a treatments in a subject, comprising (a) administering a liposome containing a photosensitizer and a drug to a subject and (b) irradiating targets at least one time at appropriate time(s). In particular, the irradiation is performed at least two times.

Claims (6)

1. A method for treating a tumor in a subject, comprising (a) administering a therapeutically effective dose of liposome encapsulating a photosensitizer and an anti-tumor drug to a subject, wherein the liposome comprises a lipid bilayer comprising phospholipids and an aqueous interior, (b) performing a first irradiation to the tumor tissues at the time the liposome reaches the tumors, (c) performing a second irradiation to the tumor tissues at the time the anti-tumor drug released from the liposome accumulates at the tumor tissues to a maximum amount, and optionally (d) performing third or more irradiations to the tumor tissues; wherein the photosensitizer is 2-[7S8S)-3Carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl-7.8-dihydro-2,8,12,17-tetramethyl-21H,23H-porphin-5-yl]acetic acid (chlorin e6; Ce6) and the anti-tumor drug is cis-platin, wherein Ce6 is encapsulated within the lipid bilayer and cis-platin is encapsulated within the aqueous interior, and wherein the tumor is colon and rectal cancer, lung cancer, cervical cancer, oral cancer or malignant peripheral nerve sheath tumor.

2. The method of claim 1 , wherein the administration is rectal, nasal, vaginal parenteral or topical.

3. The method of claim 1 , wherein the administration is parenteral such as intravenous, subcutaneous, intramuscular, intradermal and intraperitoneal.

4. The method of claim 1 , wherein the administration is intravenous.

5. The method of claim 1 , wherein the tumor is sarcoma.

6. The method of claim 1 , wherein the lung cancer is small cell lung cancer or non-small cell lung cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2012
From: NATIONAL TAIWAN UNIVERSITY
To: NATIONAL TAIWAN UNIVERSITY; TAIPEI MEDICAL UNIVERSITY
Reel/Frame 028730/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2012
From: CHEN, CHIN-TIN; TSAI, TSUIMIN
To: NATIONAL TAIWAN UNIVERSITY
Reel/Frame 028327/0616 →
Continuity (2)
Provisional Application 61487453 · May 18, 2011
Related Publication 20120323163A1 · Dec 20, 2012